CClinicalTrials.gg
CompletedNCT03976934Updated Nov 26, 2021

Prophylactic Administration of Alpha Blockers for Prevention of Urinary Retention in Males Undergoing Inguinal Hernia Repair Under Spinal Anaesthesia.

A Phase 1/2 interventional study of Tamsulosin and Placebo oral tablet in Inguinal Hernia and Urinary Retention, sponsored by Georgios Koukoulis. Completed at 2 sites in Greece. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-26.

Sponsored by Georgios Koukoulis · Phase 1/2, Interventional, and Prevention

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Study summary

Open inguinal hernia repair is one of the most common surgical procedures. Despite the fact that different of anesthetic procedures are proposed as alternatives to spinal anesthesia, the combination of spinal anesthesia with open inguinal hernia repair is preferred from both surgeons and patients. One disadvantage of this combination is the high incidence of post-surgery urinary retention, especially in men above 50 years old. This complication is partially attribute to overstimulation of the a1 adrenergic receivers of the bladder and the prostate. Preoperative administration of elective a1 blockers could inhibit this effect without side effects, since this drugs don't have systemic effect.

02

Conditions studied

  • Inguinal Hernia
  • Urinary Retention

Keywords

  • open inguinal hernia repair
  • spinal anaesthesia
  • urinary retention
  • elective alpha blockers
03

In context

Urinary Retention

235 studies on the registry are indexed under Urinary Retention; 39 are open to participants now.

This study's enrollment of 100 is close to the median of 95 across 185 interventional studies indexed under Urinary Retention.

Browse Urinary Retention studies →

Lead sponsor

This is the only study on the registry with Georgios Koukoulis as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • unilateral inguinal hernia

Exclusion criteria

Exclusion Criteria:

  • ASA score >3
  • hypotension
  • prostatic hypertrophy
  • complicated inguinal hernia
  • neurological diseases
  • inguinal hernia repair under general or local anaesthesia
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Tamsulosin group

    administration of 0,4mg of tamsulosin 24 hours before surgery and 0,4mg 6 hours before surgery

    Drug: Tamsulosin

  • Placebo comparator
    Placebo group

    administration of placebo 24 and 6 hours before surgery

    Drug: Placebo oral tablet

Interventions

  • DrugTamsulosin

    administration of tamsulosin tablets

    Also known as: omnic tocas

  • DrugPlacebo oral tablet

    sugar pills

06

What researchers measure

Primary outcomes

  1. incidence of urinary retention

    inability to voluntarily void urine up to 8 hours post surgery

    Time frame: 8 hours post surgery

Secondary outcomes

  1. Prostate related Symptoms

    identification of Prostate related Symptoms as preoperative risk factor of post surgery urinary retention. For the assessment of the prostate related symptomatology will be used the International Prostate Symptom Score questionnaire

    Time frame: Baseline

  2. Scrotal hernia Repair

    evaluation of Scrotal hernia repair as preoperative risk factor of post surgery urinary retention.

    Time frame: Baseline, Inta-operative

  3. Duration of Surgery

    Evaluation of the surgery duration as inta-operative risk factor of post surgery urinary retention.

    Time frame: Duration of Surgical procedure

  4. Use of opioids

    Evaluation of the peri-operative administration of iv opioids as a peri-operative risk factor of post surgery urinary retention.

    Time frame: 24 hours

  5. Iv fluid administration

    Evaluation of the peri-operative iv fluid administration as a peri-operative risk factor of post surgery urinary retention.

    Time frame: 24 hours

  6. Post-operative Pain

    Evaluation of the post operative pain as a risk factor of post surgery urinary retention. For the assessment of the pain will be used the Visual Analog Scale (VAS) score at 6, 12 and 24 hours after surgery. (VAS Score Scale from 0-10, 0 no pain, 10 max pain)

    Time frame: 24 hours

07

Study locations

2 sites
  • University General Hospital of Larissa
    Larissa, 41110, Greece
  • General Hospital Of Larissa
    Larissa, 41221, Greece
08

References and documents

Publications

  • Clancy C, Coffey JC, O'Riordain MG, Burke JP. A meta-analysis of the efficacy of prophylactic alpha-blockade for the prevention of urinary retention following primary unilateral inguinal hernia repair. Am J Surg. 2018 Aug;216(2):337-341. doi: 10.1016/j.amjsurg.2017.02.017. Epub 2017 Mar 14. PubMed 28341140 ↗
  • Basheer A, Alsaidi M, Schultz L, Chedid M, Abdulhak M, Seyfried D. Preventive effect of tamsulosin on postoperative urinary retention in neurosurgical patients. Surg Neurol Int. 2017 May 10;8:75. doi: 10.4103/sni.sni_5_17. eCollection 2017. PubMed 28584678 ↗
  • Shaw MK, Pahari H. The role of peri-operative use of alpha-blocker in preventing lower urinary tract symptoms in high risk patients of urinary retention undergoing inguinal hernia repair in males above 50 years. J Indian Med Assoc. 2014 Jan;112(1):13-4, 16. PubMed 25935942 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03976934
Lead sponsor
Georgios Koukoulis
Collaborators
University of Thessaly
Responsible party
Georgios Koukoulis (General Surgery Consultant, General Hospital of Larissa) — Sponsor-investigator
First posted
Jun 6, 2019
Start date
Feb 1, 2020
Primary completion
Oct 1, 2021
Completion
Oct 30, 2021
Last update
Nov 26, 2021

Study contacts

Konstantinos Tepetes, MD, PHD
study chair · University Hospital of Larisa and Medical School, University of Thessaly
Georgios D Koukoulis, MD, PhD
principal investigator · General Hospital of Larissa
Konstantinos Mpouliaris, MD
principal investigator · General Hospital of Larissa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion